| Name | LY2811376 |
| Description | LY2811376, an orally available non-peptidic β-secretase(BACE1) inhibitor (IC50: 239-249 nM), can decrease Aβ secretion (EC50: 300 nM). It has 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including pepsin, cathepsin D, or renin. |
| Cell Research | The cytotoxicity in the HEK293Swe cell model is assessed using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. (Only for Reference) |
| Kinase Assay | Determination of enzymatic ef?ciency: The stock solution for each FRET peptide substrate is prepared at 30 mM in dimethylsulfoxide (DMSO). The huBACE1:Fc muBACE1:Fc preparation is concentrated through YM10 Centricon. to a ?nal concentration of at least 7 mg/mL. The optimal enzyme concentration for each FRET peptide substrate is determined individually at 30 μM FRET peptide substrate in 50 mM ammonium acetate, pH 4.6, 1 mg/mL BSA and 1 mM Triton X-100. The enzymatic ef?ciency (kcat /Km) of either of the BACE1 orthologs toward individual FRET peptide substrates at 15, 30 and 100 μM is determined under the optimal conditions for each substrate. The progress of the reaction is monitored by measuring an increase of the emission signal at 420 nm with excitation wavelength set at 320 nm, using a GEMINI ?uorescence plate reader. Amino acid conjugated aminobenzoate is used to convert the emission signal in the relative ?uorescence units into the molar concentration of product generated in the reaction mixture. The initial phase of the timedependence curve is ?tted with a linear function whose slope is used to calculate the initial rate for huBACE1:Fc toward each peptide substrate. The kcat /Km values are calculated from the linear dependence of the initial rate on the concentration of each peptide. |
| In vitro | In the APPV717F mouse model of Aβ pathology, LY2811376 (10/30/100 mg/kg) induced a dose-dependent significant reduction in Aβ, sAPPβ, and C99, which are the closest breakdown products following the hydrolysis of APP by BACE1 protein. In beagle dogs, LY2811376 (5 mg/kg) resulted in a decrease in plasma Aβ1-x levels, with the maximum reduction of 85% occurring between 4-12 hours post-administration. |
| In vivo | LY2811376 exhibits a concentration-dependent reduction in the secretion of Aβ in HEK293 cells overexpressing APP. It also concentration-dependently inhibits hBACE1, including small synthetic peptide substrates (IC50: 239 nM) and larger chimeric protein substrates (IC50: 249 nM). In primary neuronal cultures from PDAPP transgenic mice, LY2811376 inhibits Aβ secretion (EC50: 100 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 13 mg/mL (40.6 mM)
Ethanol : 60 mg/mL (187.3 mM)
|
| Keywords | Inhibitor | LY 2811376 | LY-2811376 | LY2811376 | BACE | β-Secretase | inhibit | Beta-secretase |
| Inhibitors Related | Anle138b | BSBM7 | Notoginsenoside R1 | Geniposide | Deferoxamine Mesylate | Tramiprosate | Auraptene | Dihydroergocristine mesylate | Rutin | Phytic acid potassium | Methyl tridecanoate | Ginsenoside Re |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Hypertension Compound Library |
United States
